• Phosphatase Inhibitor Cocktail 3: Decoding Protein Phosphory

  2026-04-20

  Explore how Phosphatase Inhibitor Cocktail 3 (100X in DMSO) enables precise protein phosphorylation preservation and advanced phosphoprotein analysis. Uniquely, this article offers a mechanistic perspective and decision-making insights for optimizing serine/threonine phosphatase inhibition.

• MLN8237 (Alisertib): Applied Workflows in Cancer Biology

  2026-04-20

  MLN8237 (Alisertib) stands out as a highly selective Aurora A kinase inhibitor, enabling precise control over mitotic progression, apoptosis induction, and tumor growth inhibition in preclinical models. This guide translates the latest mechanistic findings and protocol refinements into actionable strategies for cancer research teams seeking robust, reproducible, and insightful results.

• Neticonazole Hydrochloride: Dual-Action Imidazole Antifungal

  2026-04-19

  Neticonazole Hydrochloride is a dual-action imidazole antifungal that inhibits both fungal cell membrane synthesis and tumor-promoting exosome secretion. Its efficacy in treating cutaneous candidiasis and modulating colorectal cancer pathways is supported by quantitative, peer-reviewed data. This dossier summarizes key mechanisms, use protocols, and boundaries for translational research.

• FLAG tag Peptide (DYKDDDDK): Precision in Protein Purificati

  2026-04-18

  The FLAG tag Peptide (DYKDDDDK) enables gentle, high-specificity purification of recombinant proteins, as proven in state-of-the-art Mediator complex isolation protocols. This article demystifies experimental workflows, key troubleshooting maneuvers, and practical integration strategies to unlock reliable, reproducible results in advanced protein research.

• Canagliflozin Hemihydrate: Precision SGLT2 Inhibitor for Met

  2026-04-17

  Canagliflozin hemihydrate, supplied by APExBIO, offers unrivaled specificity and solubility for research into glucose homeostasis pathways and renal glucose reabsorption. Its validated purity and workflow flexibility set a new standard for diabetes and metabolic disorder experimentation, clearly distinguishing it from mTOR-targeted strategies.

• Mitochondrial Calcium Signaling Regulates Ferroptosis via GP

  2026-04-16

  This study reveals that mitochondrial calcium uptake, mediated by the mitochondrial calcium uniporter (MCU), is essential for maintaining GPX4 activity and repressing ferroptosis in cancer cells. The findings provide mechanistic insight into how mitochondrial metabolism and calcium signaling intersect to control cell fate, with translational implications for ferroptosis-targeted therapies.

• Rapamycin (Sirolimus): Applied mTOR Inhibition in Cell Assay

  2026-04-15

  Rapamycin (Sirolimus) from APExBIO delivers precise, nanomolar-scale mTOR inhibition, enabling researchers to dissect cell proliferation, immune modulation, and autophagy dysfunction across disease models. This article translates advanced mechanistic insights into actionable assay design, troubleshooting, and protocol optimization for cutting-edge cell biology and immunology studies.

• CA-074: Selective Cathepsin B Inhibitor for Cancer Research

  2026-04-14

  CA-074 is a potent cathepsin B inhibitor used to dissect protease-driven pathways in cancer metastasis and neurodegeneration. Its high selectivity and nanomolar affinity enable precise modulation of cell death and immune responses in preclinical models.

• Cathepsin B Inhibition: Next-Gen Strategies in Necroptosis &

  2026-04-13

  This thought-leadership article explores the mechanistic, experimental, and translational frontiers of targeting cathepsin B with CA-074. We synthesize recent advances in lysosomal membrane permeabilization and necroptosis, highlight the role of cathepsin B in cancer metastasis and neurotoxicity, and offer strategic guidance for researchers leveraging APExBIO’s CA-074 in cutting-edge disease modeling and therapeutic innovation.

• EdU Flow Cytometry Assay Kits (Cy3): Precision in Cell Cycle

  2026-04-12

  EdU Flow Cytometry Assay Kits (Cy3) deliver denaturation-free, high-sensitivity cell proliferation analysis for flow cytometry and multiplex workflows. Leveraging click chemistry, these kits empower research in oncology, genotoxicity testing, and pharmacodynamic studies with superior workflow flexibility and compatibility. See how APExBIO's solution accelerates breakthrough discoveries, including recent advances in triple-negative breast cancer.

• Dasatinib Monohydrate: Optimizing CML and Ph+ ALL Research W

  2026-04-12

  Dasatinib Monohydrate (BMS-354825) empowers translational scientists to dissect kinase-driven resistance, model vascular complications, and precisely control BCR-ABL signaling in advanced leukemia research. Leverage APExBIO’s rigorously characterized compound for robust, reproducible results—especially in imatinib-resistant and Philadelphia chromosome-positive models.

• Omeprazole (A2845): Protocol-Driven Use in Gastric Acid Rese

  2026-04-11

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor for the study of gastric acid secretion and antiulcer mechanisms in preclinical models. It is not intended for diagnostic or therapeutic applications, and its use should be strictly limited to research workflows involving proton pump inhibition and related gastric acid-related disorders.

• Trametinib (GSK1120212): Optimizing MEK Inhibitor Assays in

  2026-04-11

  Trametinib (GSK1120212) stands out as a precise ATP-noncompetitive MEK1/2 inhibitor, enabling robust G1 arrest and apoptosis induction in cancer cell models. This guide distills leading-edge workflows, troubleshooting, and real-world data—anchored in peer-reviewed research and APExBIO’s high-purity reagent supply—to empower reproducible, high-impact oncology studies.

• Elobixibat Hydrate: Mechanistic Insights and Translationa...

  2026-04-10

  This thought-leadership article demystifies the mechanistic and translational landscape surrounding Elobixibat hydrate, a highly selective inhibitor of the ileal bile acid transporter (IBAT). By blending biochemical rationale, pivotal clinical data, and actionable guidance, we empower researchers and clinicians to maximize the therapeutic and experimental potential of bile acid transporter modulation in chronic idiopathic constipation and type 2 diabetes mellitus (T2DM). Integrating evidence from recent clinical studies and scenario-driven research workflows, we position Elobixibat hydrate as a benchmark tool for advancing both fundamental discovery and translational impact.

• Elobixibat Hydrate: Precision IBAT Inhibition and Transla...

  2026-04-09

  Explore the advanced pharmacological and translational science of Elobixibat hydrate, a selective ileal bile acid transporter inhibitor for chronic idiopathic constipation and metabolic modulation in type 2 diabetes mellitus. This article uniquely dissects its enterohepatic impact, clinical utility, and future metabolic applications.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page